Introduction: Peripheral neuropathy can affect patients with heart failure, though its prevalence is unknown. After heart transplantation, it can influence the postoperative course and quality of life, but screening for neuromuscular disease is not routinely performed. Objective: The aim of this study was to identify the factors associated with neuropathy in a population of patients with heart failure who are candidates for heart transplantation. Study Design: Data regarding patients' clinical history, including recent hospitalizations, were collected. All patients underwent a complete neurological examination and a neurophysiological protocol including nerve conduction studies and concentric needle electromyography. Results: Thirty-two patients were included in the study, and neuropathy was diagnosed in 10 (31.3%). Neuropathy was associated with the number of admissions (P ¼ .023; odds ratio [OR]: 1.96) and the total number of days of hospitalization in the year prior to inclusion in the study (P ¼ .010; OR: 1.03). The majority of hospitalizations occurred in the step-down unit (85%), with acute heart failure the leading cause of admission (42%). Conclusions: This study shows that neuropathy is frequent in patients with advanced heart failure and that hospitalization for cardiac care, also in the absence of intensive care, is a marker of high risk of neurologic damage. These data can help physicians in selecting and managing candidates for transplantation and can guide decisions on the best immunosuppressive regimen or rehabilitation strategy.
Introduction
Heart transplantation is the treatment of choice for patients with end-stage heart failure (HF) despite optimized medical treatment. 1 However, due to the shortage of available organs, only a minority of select patients among all potential candidates can be inserted in waiting list for transplantation. A central role in the most proper allocation of the organs is the evaluation of absolute and relative contraindications to surgery that may negatively influence the outcome. 2 Patients with HF can develop neuropathy, though its presence is not systematically investigated during workup. 3 Peripheral neuropathy is a disease affecting nerves, which may induce a combination of altered sensation, pain, weakness, or autonomic symptoms. 4 Data in the literature show that neuromuscular diseases occur more often after surgery and influence functional recovery. [5] [6] [7] [8] A previous study from our group found that neuromuscular disorders are common in heart transplantation candidates and occur more frequently after heart transplantation. 9 In patients who have undergone heart transplantation, the appearance of neuropathy during the postoperative course can negatively impact on the short-term outcome, while chronic immunosuppressive therapy may worsen preexisting neuromuscular damage, thus influencing quality of life. [10] [11] [12] [13] At present, the causes of neurologic damage in patients with advanced cardiac disease are not well defined. Some evidence suggest that the onset of neuropathy is a consequence of prolonged admissions in intensive care units (ICUs) and that immune activation and inflammatory cytokines release are involved in neuromuscular damage. We hypothesized that advanced heart disease and frequent hospitalizations may involve pathophysiological changes responsible for neuromuscular damage. The aim of this study was to identify factors that are potentially associated with development of neuropathy in a population of patients affected with severe HF and who are candidates for heart transplantation.
Methods Population
All patients on our waiting list for heart transplantation who agreed to sign informed written consent were considered eligible for the study. Exclusion criteria were as follows: (1) previous history of neuromuscular disease or systemic disease involving the nervous system; (2) history of alcohol abuse; (3) patients with hemodynamic instability requiring urgent transplantation, who were inotrope-dependent, or who were not able to undergo to a full neurologic evaluation; and (4) patient's refusal to undergo neurological assessment. The study was approved by our institute's ethics committee and by the San Raffaele G. Giglio Institute Foundation Ethics Committee in accordance with the guidelines of the Helsinki Declaration.
Data Collection
Demographic and clinical data were collected from the patients' medical files. The following clinical data were included: history of arterial hypertension, diabetes mellitus, hypercholesterolemia, and smoking; previous cerebral ischemic events; renal function (evaluated in creatinine clearance); etiology of cardiomyopathy, New York Heart Association (NYHA) class; left ventricular assist device (L-VAD) in place as a bridge to transplantation; cardiac disease duration since diagnosis; number of hospital admissions and total number of days of hospitalization in the year prior to inclusion in the study; and number and type of medications. All data were recorded in a dedicated database.
Clinical and Neurophysiological Evaluations
All patients underwent a complete clinical neurological examination carried out by neurologists and an electroneurographic and electromyographic evaluation including nerve conduction studies and concentric needle electromyography (EMG). Neurophysiological studies were done with a Micromed System PLUS Evolution EMG (Mogliano Veneto, Italy). Surface electrodes were used for stimulation and recording, except for sensory nerve action potential (SNAP) recording, which was made with subdermal electrodes in the case of edema. The ulnar, deep peroneal, and sural nerves were studied bilaterally in a typical evaluation. Motor nerve conduction measurements included: (1) compound muscle action potential amplitude and latency in the hands and feet in response to distal nerve stimulation and (2) motor conduction velocity in the forearm or leg. Compound muscle action potentials were recorded from the abductor digiti minimi and extensor digitorum brevis muscles after stimulating the ulnar and deep peroneal nerves at the wrist and ankle at a distance of 6 and 8 cm, respectively, from the recording electrode. Sensory nerve conduction studies included SNAP amplitude to antidromic nerve stimulation and sensory conduction velocity in the finger or ankle.
Qualitative concentric needle EMG was performed on the proximal and distal limb muscles to evaluate spontaneous activity, such as fibrillation potentials, positive sharp waves, and voluntarily activated motor unit action potentials. At least 8 muscles per patient were studied. The deltoid, first dorsal interosseous, quadriceps femoris, and tibialis anterior muscles were studied bilaterally in a typical evaluation, though some patients underwent more detailed examinations, in particular, in the case of pathological findings in the standard evaluation. In the nerve conduction studies, the normal limits were defined as the mean plus or minus 2 standard deviations (SDs) of age-matched normative data from our laboratory. In the nerve conduction studies, data below normal limits were considered pathological. In the EMG evaluation, pathological values regarding both spontaneous activity and voluntarily activated motor unit action potentials came from a visual analysis.
Statistical Analysis
Variables are expressed as counts and percentage if categorical and means (SD) if continuous. All clinical data were stratified by complete neurological examination, by nerve conduction studies, and by a concentric needle EMG. Furthermore, we also compared those variables that were different in patients with or without abnormal nerve conduction studies by the kind of fibers affected by neuropathy: sensory and motor versus sensory alone. Statistical analyses were done by independent Student t test assuming unequal variances, Wilcoxon rank sum (Mann-Whitney) test, median test, and Fisher exact test, as necessary. Univariate logistic regression was used to test association between hospitalization data (number of admissions and total number of hospitalization days) and risk of neuropathy as assessed by abnormal physical examination, as well as pathological EMG or electroneurography (primary outcomes). A 2-sided P value of <.05 was considered statistically significant. Data handling and analyses were done with STATA version 13.1 software (College Station, Texas).
Results
This study included 32 patients who were candidates for heart transplantation. Eleven patients were excluded because of HF with hemodynamic instability, while 3 patients refused to participate in the study. Baseline population characteristics are reported in Table 1 . The cardiac disease leading to HF was ischemic cardiomyopathy in 15 (47%) patients, idiopathic cardiomyopathy in 10 (31%), and heterogeneous etiologies in 7 (21%).
In 7 (22%) patients, a L-VAD (Heartware, Framingham, Massachusetts, USA) had been implanted at least 3 months before inclusion on the heart transplant waiting list. The NYHA class was evaluated after the inclusion and revealed 13 (41%) patients in class II and 19 (59%) patients in class III. Cardiac disease duration was 14 (7.5) years (range: 0.4 to 38 years). The mean number of admissions in the year prior to inclusion in the study for each patient was 3 (1.5), while the mean total number of hospitalization days was 46 (38) . The majority of admissions (85%) occurred in the step-down unit.
The neurological examination revealed signs suggesting a neuromuscular involvement in 17 (53%) patients. The neurophysiological examination showed abnormal sensory nerve conduction in 4 (12%) patients, abnormal sensory and motor conduction in 6 (19%), and abnormal electromyographic findings in 14 (44%). A neuropathy was diagnosed in 10 (31%) patients; a detailed description of neurological disorders is presented in Table 2 .
Analysis of the factors potentially associated with neuropathy is reported in Table 3 . In detail, the number of admissions and the length of stay (total number of days of hospitalization) during the last year was significantly higher in patients with neuromuscular involvement in the neurological examination (P ¼ .0022 and P ¼ .0006). A higher incidence of abnormal EMG results was found in patients with a greater total number of days of hospitalization in the year prior to inclusion in the study (P ¼ .0075), but not in those with a greater number of admissions. A pathological nerve conduction study consistent with a diagnosis of neuropathy was associated with both the total number of days of hospitalization (P ¼ .0117) and the number of admissions in the prior year (P ¼ .0059). History of L-VAD implantation (P ¼ .008) and NYHA class II (P ¼ .036) were associated with neurologic abnormalities at physical examination where no association with cardiac disease etiology and duration was found (P ¼ .10 and P ¼ .50, respectively). An abnormal EMG was found in patients currently supported by the L-VAD bridge (P ¼ .027), while no association was found with cardiac disease etiology (P ¼ .66), NYHA class (P ¼ .14), or cardiac disease duration (P ¼ .61). Cardiomyopathy etiology, cardiac illness duration, NYHA class, and L-VAD use were not correlated with a full diagnosis of neuropathy (P > .05). Among patients diagnosed with neuropathy, no association between a specific type of neuropathy (sensory and motor or sensory alone) and the variables analyzed was found (data not shown).
Logistic Regression
Simple logistic regression analysis showed that both the total number of days of hospitalization (P ¼ .01; odds ratio [OR]: 1.0) and the number of admissions in the prior year (P ¼ .01; OR: 2.2) were predictors of pathological objective examination, while only the total number of days of hospitalization increased the risk of a pathological EMG (P ¼ .019; OR: 1.02). Also, either the total number of days of hospitalization (P ¼ .01; OR: 1.0) or the number of admissions (P ¼ .02; OR 1.96) increased the risk of a pathological nerve conduction study consistent with a full diagnosis of neuropathy (Table 4) .
Discussion
The occurrence of neuropathy in patients with end-stage HF is not well understood and its prevalence in this population is still unknown. Malheiros et al examined a population of 120 patients (62 had undergone transplantation) with cardiac insufficiency caused mainly by Chagas disease and found neurologic complications after heart transplantation in 19 (31%) patients, 4 of whom had peripheral neuropathy. 14 In our study, we systematically looked for neuropathy in patients on the waiting list for transplantation at our center. Analysis revealed that more than half showed signs of neuromuscular alterations and about one-third had a full diagnosis of neuropathy with no clinical symptoms. A probable explanation for this finding is that due to severe physical limitations caused by cardiac disease, neuropathy was asymptomatic or with mild symptoms.
There are little data in the literature on the causes and mechanisms responsible for neuromuscular damage and no specific studies have been conducted on patients affected with end-stage HF. There is evidence to suggest that the onset of neuropathy is a consequence of repeated or prolonged hospital (2) 2 (100) 0 (0) 1 (50) 1 (50) 2 (100) 0 (0) ARVD (2) 2 (100) 0 (0) 2 (100) 0 (0) 2 (100) 0 (0) Congenital (1) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) Postmyocarditis (1) 0 (0) 1 (100) .102 0 (0) 1 (100) .667 1 (100)
No (25) 15 (60) 10 (40) 17 (68) 8 (32) 19 (76) 6 (24) Yes (7) 0 (0) 7 (100 No (18) 10 (56) 8 (44) 12 (67) 6 (33) 14 (78) 4 (22) Yes (14) 5 (36) stays in an ICU. 15, 16 Critical illness neuropathy is a clinical condition characterized by peripheral fiber involvement that cannot impute to the underlining illness and arises after long stays in an ICU. [17] [18] [19] [20] [21] [22] [23] The causes remain unclear, but sepsis, multi-organ failure, malnutrition, hyperosmolarity, parenteral nutrition, vasopressors, and catecholamine are some of the risk factors identified in previous studies conducted on ICU patients. 24, 25 In this clinical setting, the release of proinflammatory cytokines together with immune system activation or a directed toxic effect of some drugs can cause neuromuscular system damage. [26] [27] [28] [29] [30] It is well known that chronic low cardiac output stimulates the sympathoadrenal and the reninangiotensin-aldosterone systems with the production and release of systemic pro-inflammatory cytokines, such as endothelin, interleukin-6, and tumor necrosis factor a. 31 We can speculate that these cytokines, when released chronically in the systemic circulation, induce persistent neuromuscular tissue inflammation and damage.
We found an association with both the number of hospital admissions and prolonged length of hospital stay. Each additional day of in-hospital stay increased the risk of neuropathy by about 3%, and each additional hospital admission was associated with a 2-fold increase in risk. It is worth noting that the majority of the hospitalizations occurred in the step-down unit and not the ICU. These data suggest a role of the hospitalizations in the onset of neuropathy independent of intensive care. We suppose that acute adaptive neurohumoral system stimulation occurring during cardiac decompensation may play a central role in the pathogenesis of neuromuscular damage. Number and length of hospitalizations may be surrogate markers of the severity of HF whose pathophysiological changes, especially during acute phases, would be responsible for the onset of neuropathy. Previous studies indicate that cardiomyopathy etiology may be involved in the development of neuropathy, [32] [33] [34] though none of our patients had etiologies (eg, amyloidosis or Fabry disease) able to directly cause neurologic damage. The lack of association with duration of illness is most likely a consequence of the wide variability of the illness across time observed. Therefore, patients with a long history of heart disease but without frequent episodes of cardiac decompensation do not seem to be at risk of developing neuropathy.
Finally, in the subpopulation of L-VAD carriers, neuropathy occurred more often than in the whole population, suggesting that the presence of the mechanical device is linked to a major susceptibility to developing nervous system damage. Whether the cause is the device or is only a marker of a more severe disease remains unclear.
Discovery of neuropathy does not constitute itself a contraindication for heart transplant but can lengthen the time of hospitalization after surgery increasing the risk of complications. Therefore, screening for neuropathy can contribute to perioperative risk stratification and can guide in rehabilitation. 35, 36 Besides, it could aid in clinical decisions on the best immunosuppressive regimen helping physicians to choose drugs with less toxicity on the neuromuscular system or to optimize their dosage. [37] [38] [39] More generally, our data suggest that all patients with end-stage HF having frequent hospitalizations, independently of being candidates for transplantation, are at risk of developing neuropathy; consequently, in the framework of multidisciplinary outpatient management, it can be important to carry out a neurological follow-up that would allow early identification of neuromuscular disorders and set up a rehabilitation program with improvement in quality of life.
This study has some obvious limitations, foremost the small cohort size. Larger studies would add valuable information to this setting. Another limitation is the lack of sufficient followup data, due to the small number of patients who actually underwent transplantation, making for too small a cohort to study. We are currently planning to evaluate neurological function pre-and posttransplant.
Conclusions
We found that neuropathy is frequent in patients with advanced HF despite the absence of specific neurologic symptoms. Knowledge of risk factors associated with neuropathy would be a useful tool to improve the management of heart transplant candidate patients. Our data indicate that increased number of admissions and length of stay of hospitalization, even when not in the ICU, are markers of high risk. Additional studies enrolling a larger patient population are needed to confirm our results.
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